One of them, galunisertib (LY2157299) is being evaluated for efficacy and safety including inhibition of TGF-β signaling in advanced hepatocellular cancer patients undergoing radiotherapy through a phase I clinical study (NCT02906397). Here, TGFB1 is linked to hepatocellular carcinoma.